Skip header and navigation

6 records – page 1 of 1.

5-Aminosalicylate (5-ASA)

https://libcat.nshealth.ca/en/permalink/chpams35397
Nova Scotia Health Authority. Central Zone. Gastroenterology. Halifax, NS: Nova Scotia Health Authority , 2016.
Pamphlet Number
1483
Available Online
View Pamphlet
5-aminosalicylate (5-ASA) is a type of drug often used to treat inflammatory bowel disease (IBD). This type of drug is good at controlling active ulcerative colitis or Crohn’s colitis as well as keeping ulcerative colitis in remission. Topics include: what 5-ASA type drugs do, which 5-ASA you should take, continuing to take the drug, talking to your doctor, what other medication you can take, and when to expect to see improvement. The pamphlet also describes common and rare side effects.
Available Online
View Pamphlet
Corporate Author
Nova Scotia Health Authority. Central Zone. Gastroenterology
Place of Publication
Halifax, NS
Publisher
Nova Scotia Health Authority
Date of Publication
2016
Format
Pamphlet
Language
English
Physical Description
1 electronic document (6 p.) : digital, PDF file
Subjects (MeSH)
Inflammatory Bowel Diseases - drug therapy
Crohn Disease - drug therapy
Colitis - drug therapy
Subjects (LCSH)
Inflammatory bowel diseases
Crohn's disease
Colitis
Abstract
5-aminosalicylate (5-ASA) is a type of drug often used to treat inflammatory bowel disease (IBD). This type of drug is good at controlling active ulcerative colitis or Crohn’s colitis as well as keeping ulcerative colitis in remission. Topics include: what 5-ASA type drugs do, which 5-ASA you should take, continuing to take the drug, talking to your doctor, what other medication you can take, and when to expect to see improvement. The pamphlet also describes common and rare side effects.
Responsibility
Prepared by: Jennifer Stewart, RN; Gastroenterology
Prepared by: Kaleigh MacIsaac, B.ScPharm; Gastroenterology
Revised by: Phyllis Durning, RN
Revised by: Alison Harding, B.Sc.
Pamphlet Number
1483
Less detail

Adalimumab (Humira) therapy

https://libcat.nshealth.ca/en/permalink/chpams35127
Nova Scotia Health Authority. Central Zone. Gastroenterology. Halifax, NS: Nova Scotia Health Authority , 2016.
Pamphlet Number
1207
Available Online
View Pamphlet
Your healthcare provider feels that treatment with adalimumab may be helpful in managing your inflammatory bowel disease (IBD). This pamphlet describes what adalimumab is and some important aspects of therapy with this medication. Precautions and possible side effects are listed.
Available Online
View Pamphlet
Corporate Author
Nova Scotia Health Authority. Central Zone. Gastroenterology
Place of Publication
Halifax, NS
Publisher
Nova Scotia Health Authority
Date of Publication
2016
Format
Pamphlet
Language
English
Physical Description
1 electronic document (9 p.) : digital, PDF file
Subjects (MeSH)
Adalimumab
Inflammatory Bowel Diseases - drug therapy
Subjects (LCSH)
Inflammatory bowel diseases
Specialty
Medications
Abstract
Your healthcare provider feels that treatment with adalimumab may be helpful in managing your inflammatory bowel disease (IBD). This pamphlet describes what adalimumab is and some important aspects of therapy with this medication. Precautions and possible side effects are listed.
Responsibility
Prepared by: Division of Gastroenterology
Pamphlet Number
1207
Less detail

Azathioprine (Imuran) therapy

https://libcat.nshealth.ca/en/permalink/chpams35565
Nova Scotia Health Authority. Central Zone. Gastroenterology. Halifax, NS: Nova Scotia Health Authority , 2015.
Pamphlet Number
1079
Available Online
View Pamphlet
This pamphlet provides information about azathioprine (Imuran®) therapy, an immunosuppressive drug. The pamphlet explains what azathioprine is, how well it works, as well as potential minor and major side-effects. The pamphlet also includes a list of what you can do to lower the chances of side-effects.
Available Online
View Pamphlet
Corporate Author
Nova Scotia Health Authority. Central Zone. Gastroenterology
Place of Publication
Halifax, NS
Publisher
Nova Scotia Health Authority
Date of Publication
2015
Format
Pamphlet
Language
English
Physical Description
1 electronic document (6 p.): digital, PDF file
Subjects (MeSH)
Immunosuppressive Agents
Azathioprine
Subjects (LCSH)
Immunosuppressive agents
Specialty
Gastroenterology
Abstract
This pamphlet provides information about azathioprine (Imuran®) therapy, an immunosuppressive drug. The pamphlet explains what azathioprine is, how well it works, as well as potential minor and major side-effects. The pamphlet also includes a list of what you can do to lower the chances of side-effects.
Responsibility
Updated by: Jennifer Stewart, RNCCRP; Tim Mombourquette (GI Research Student)
Pamphlet Number
1079
Less detail

Infliximab (Remicade) therapy

https://libcat.nshealth.ca/en/permalink/chpams34944
Nova Scotia Health Authority. Central Zone. Gastroenterology. Halifax, NS: Nova Scotia Health Authority , 2016.
Pamphlet Number
1140
Available Online
View Pamphlet
Your healthcare provider feels that treatment with infliximab may be helpful in managing your inflammatory bowel disease (IBD). This pamphlet describes what infliximab is and some important aspects of therapy with this medication. Precautions and possible side effects are listed.
Available Online
View Pamphlet
Corporate Author
Nova Scotia Health Authority. Central Zone. Gastroenterology
Place of Publication
Halifax, NS
Publisher
Nova Scotia Health Authority
Date of Publication
2016
Format
Pamphlet
Language
English
Physical Description
1 electronic document (9 p.) : digital, PDF file
Subjects (MeSH)
Inflammatory Bowel Diseases - drug therapy
Infliximab
Subjects (LCSH)
Inflammatory bowel diseases
Infliximab
Abstract
Your healthcare provider feels that treatment with infliximab may be helpful in managing your inflammatory bowel disease (IBD). This pamphlet describes what infliximab is and some important aspects of therapy with this medication. Precautions and possible side effects are listed.
Responsibility
Prepared by: Division of Gastroenterology
Pamphlet Number
1140
Less detail

Methotrexate therapy for inflammatory bowel disease (IBD)

https://libcat.nshealth.ca/en/permalink/chpams34942
Nova Scotia Health Authority (Central Zone). Gastroenterology. Halifax, NS: Nova Scotia Health Authority , 2015.
Pamphlet Number
1138
Available Online
View Pamphlet
This pamphlet provides information about taking Methotrexate to treat inflammatory bowel disease (IBD). The pamphlet describes what Methotrexate does, and how well it works. Lists of minor and serious side effects are included. The pamphlet explains who should not take Methotrexate, and precautions you will need to take while on the treatment. The pamphlet outlines instructions about injecting Methotrexate. These instructions include what to do beforehand, how to prepare and give the injection…
Available Online
View Pamphlet
Corporate Author
Nova Scotia Health Authority (Central Zone). Gastroenterology
Place of Publication
Halifax, NS
Publisher
Nova Scotia Health Authority
Date of Publication
2015
Format
Pamphlet
Language
English
Physical Description
1 electronic document (12 p.) : digital, PDF file
Subjects (MeSH)
Methotrexate
Crohn's disease
Inflammatory Bowel Diseases
Immunosuppressive Agents
Subjects (LCSH)
Crohn's disease
Methotrexate
Immunosuppressive agents
Inflammatory bowel diseases
Specialty
Gastroenterology
Abstract
This pamphlet provides information about taking Methotrexate to treat inflammatory bowel disease (IBD). The pamphlet describes what Methotrexate does, and how well it works. Lists of minor and serious side effects are included. The pamphlet explains who should not take Methotrexate, and precautions you will need to take while on the treatment. The pamphlet outlines instructions about injecting Methotrexate. These instructions include what to do beforehand, how to prepare and give the injection, where to inject the treatment, and what to do if you get Methotrexate on your skin, work area, or in your eye.
Responsibility
Updated by: Tim Mombourquette (GI Research Student) & Jennifer Stewart RNCCRP
Pamphlet Number
1138
Less detail

Vedolizumab (Entyvio) therapy

https://libcat.nshealth.ca/en/permalink/chpams35620
Nova Scotia Health Authority. Central Zone. Gastroenterology. Halifax, NS: Nova Scotia Health Authority , 2016.
Pamphlet Number
1623
Available Online
View Pamphlet
Vedolizumab (Entyvio®) is given to manage inflammatory bowel disease (IBD), ulcerative colitis, or Crohn's disease. In this pamphlet you will find information to help you make an informed decision about whether or not use this treatment. Topics include: a brief description of the medicine, who can take it, how it works, how it is given, precautions, side effects, symptoms to watch out for, pregnancy & breastfeeding, and other important things to know when undergoing this treatment.
Available Online
View Pamphlet
Corporate Author
Nova Scotia Health Authority. Central Zone. Gastroenterology
Place of Publication
Halifax, NS
Publisher
Nova Scotia Health Authority
Date of Publication
2016
Format
Pamphlet
Language
English
Physical Description
1 electronic document (9 p.) : digital, PDF file
Subjects (MeSH)
Gastrointestinal Agents
Colitis, Ulcerative - drug therapy
Crohn Disease - drug therapy
Subjects (LCSH)
Gastrointestinal agents
Ulcerative colitis
Crohn's disease
Abstract
Vedolizumab (Entyvio®) is given to manage inflammatory bowel disease (IBD), ulcerative colitis, or Crohn's disease. In this pamphlet you will find information to help you make an informed decision about whether or not use this treatment. Topics include: a brief description of the medicine, who can take it, how it works, how it is given, precautions, side effects, symptoms to watch out for, pregnancy & breastfeeding, and other important things to know when undergoing this treatment.
Responsibility
Prepared by: Allison Harding BSc & Jennifer Stewart RN, CCRP; Division of Gastroenterology
Pamphlet Number
1623
Less detail

6 records – page 1 of 1.